Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 907-912

  Nakano, T ^a   Chahinian, A P ^b   Shinjo, M ^a   Tonomura, A ^a   Miyake, M ^a   Togawa, N ^a   Ninomiya, K ^a   Higashino, K ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Acute phase protein; Interleukin 6; Irinotecan; Mesothelioma; Thrombocytosis; Tuberculous pleurisy

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; OROSOMUCOID;

ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUBERCULOUS PLEURISY;

EID: 0031938619     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.150     Document Type: Article

References (38)

1. Akira S and Kishimoto T (1992) The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol 3: 17-26
2. Bataille R, Jourdan M, Zhang X-G and Klein B (1989) Interleukin-6 is a potent growth factor for plasma cells and is elevated in overt myeloma and plasma cell leukemia. J Clin Invest 84: 2008-2011
3. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BW and Fitzpatrick DR (1995a) Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 40: 241-250
4. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Musk AW and Robinson BW (1995b) Potential for interferon-α-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 15: 213-223
5. Blay JY, Negrier S, Combaret V, Altali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskoytchenko JF and Philip T (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
6. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T and Heinrich PC (1990) Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by IL-6. Hepatology 12: 1179-1186
7. Chahinian AP and Pajak T (1982) Diffuse malignant mesothelioma: prospective evaluation of 69 cases. Ann Intern Med 96: 746-755
8. Donna A, Betta P and Jones JSP (1989) Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody. Cancer 63: 1331-1336
9. Duncan MR and Berman B (1991) Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97: 686-692
10. Gallo O, Gori AM, Atlanasio M, Martini F, Paola G, Storchi OF and Abbate R (1992) Acute-phase proteins and interleukin 6 serum level in head and neck cancer. Arch Otolaryngol Head Neck Surg 118: 1366-1367
11. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T and Heinrich PC (1988) Induction of rat acute-phase proteins by interleukin-6 in vivo. Eur J Immunol 18: 717-721
12. Higashihara M, Sunaga S, Tange T, Oohashi H and Kurokawa K (1992) Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer 70: 2105-2108
13. Hirano T, Teranishi T, Toba H, Sakaguchi N, Fukukawa T and Tsuyuguchi I (1981) Human helper T cell factor(s). Partial purification and characterization J Immunol 126: 517-522
14. Holt I, Cooper RG and Hopkins SJ (1991) Relationship between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 21: 479-484
15. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F and Akiyama Y (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241-1244.
16. Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA and Klein B (1991) Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 21: 479-484
17. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A and Kishimoto T (1988) Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85
18. Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1-10
19. Klein B, Zhang X-G, Jourdan M, Boiron J-M, Portier M, Lu Z-Y, Wijidenes J, Brochier J and Bataille R (1990) Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1: 193-201
20. Manzini VP, Brollo A and Bianchi C (1990) Thrombocytosis in malignant pleural mesothelioma. Tumori 76: 576-578
21. Miles SA, Rezai AR, Salazar-Gonzalez JF, Meyden MV, Stevens RH, Logan RT, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T and Martinez-Maza O (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87: 4068-4072
22. Monti G, Jaurand MC, Monnel I, Chretien P, Saint-Etienne L, Zeng L, Portier A, Devillier P, Galanaud P, Bignon J and Emilie D (1994) Interapleural production of interleukin 6 during mesothelioma and its moduration by γ-interferon treatment. Cancer Res 54: 4419-4423
23. Motro B, Itin A, Sachs L and Keshet E (1990) Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87: 3092-3096
24. Nagasawa T, Orita T, Matsushita J, Tsuchiya M, Neichi T, Imazeki I, Imai N, Ochi N, Kanma H and Abe T (1990) Thrombopoietic activity of human interleukin-6. FEBS Lett 260: 176-178
25. Nakano T, Fujii J, Tamura S, Amuro Y, Nabeshima K, Horai T, Hada T and Higashino K (1986a) Glycosaminoglycan in malignant pleural mesothelioma. Cancer 57: 106-110
26. Nakano T, Fujii J, Tamura S, Hada T and Higashino K (1986b) Thrombocytosis in patients with malignant pleural mesothelioma. Cancer 58: 1699-1701
27. Nijsten MW, de Groot ER, ten Duis HJ, Klasen HJ, Hack CE and Aarden LA (1987) Serum levels of interleukin-6 and acute phase responses. Lancet 2: 921
28. Nijsten MW, Hack CE, Helle M, ten Duis HJ, Klasen HJ and Aarden LA (1991) Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery 109: 761-767
29. Oliff A (1988) The role of tumor necrosis factor (cachectin) in cachexia. Cell 54: 141-142
30. Pass HI and Pogrebniak HW (1993) Malignant pleural mesothelioma. In Current Problems in Surgery, Wells SA, Austen WG, Fonkalsrud EW, Polk HC and Brenman MF. (eds) pp. 923-1012. Mosby: St Louis
31. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayouh J, Shepherd FA, Evans WK, Figueredo A, Pater JL, Pringle JF and Kreisman H (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7: 1157-1168
32. Schmitter D, Lauber B, Fagg B and Stahel RA (1992) Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51: 296-301
33. Stahel RA, O'Hara CJ, Waibel R and Martin A (1988) Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Int J Cancer 41: 218-223
34. Suzuki K, Miyashita A, Inoue Y, Iki S, Enomoto H, Takahashi Y and Takemura T (1991) Interleukin-6-producing pheochromocytorna. Acta Haematol 85: 217-219
35. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P and Fridman WH (1994) Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911-913
36. Wirth PR, Legier J and Wright GL (1991) Immunohistochemical evaluation of seven monoclonal antibodies lor differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 67: 655-662
37. Wright GL Jr, Wirth P, Chahinian AP, Beckett ML, Newhall K and Holland JF (1989) Monoclonal antibody EVHS-17. 392 differentiates malignant mesothelioma from adenocarcinomas. Proc Am Assoc Cancer Res 30: 351
38. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clerk SC, Messner HA and Minden MD (1989) A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74: 798-804